FIT for Bowel Cancer Symptoms Under 50

✓ Medically reviewed | Published: | Evidence level: 1A
A systematic review published in Gut has examined how accurately the faecal immunochemical test (FIT) detects colorectal cancer in symptomatic patients under 50 tested in primary care. The question matters because early-onset colorectal cancer is increasing in many countries, and most FIT pathways were designed and validated mainly in older adults. FIT is a useful triage tool, but it is not a substitute for clinical judgment when symptoms persist.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Oncology

Quick Facts

Test type
Stool-based blood detection
Focus group
Symptomatic adults under 50
Setting studied
Primary care
US screening age
Starts at 45

What Is the Faecal Immunochemical Test and Why Is It Used for Bowel Symptoms?

Quick answer: FIT is a stool test that detects tiny amounts of human blood, helping clinicians decide who with bowel symptoms most urgently needs a colonoscopy.

The faecal immunochemical test uses antibodies to detect human haemoglobin in a small stool sample. Colorectal cancers and some large polyps can bleed in amounts too small to see, so a result above a chosen haemoglobin threshold raises the likelihood that a lesion is present. In the United Kingdom, NICE guidance recommends FIT in primary care for adults with certain lower gastrointestinal symptoms who do not meet criteria for an immediate cancer referral. This approach helps direct limited colonoscopy capacity to patients at higher risk.

FIT is now widely used for two purposes: population screening of people without symptoms, and symptomatic triage, where a patient has already presented with concerns such as a change in bowel habit, rectal bleeding, abdominal pain, or unexplained iron-deficiency anaemia. The two uses are different. Performance and the choice of threshold depend on how common cancer is in the group tested, and symptomatic patients generally have a higher prior probability of disease than screening populations.

How Accurate Is FIT for Colorectal Cancer in Symptomatic Patients Under 50?

Quick answer: FIT can help rule cancer in or out in younger symptomatic adults, but its accuracy is less well established than in older people, and a negative result does not fully exclude disease.

The systematic review in Gut set out to pool evidence on how well FIT performs in symptomatic patients younger than 50 who are tested in primary care. This is a deliberate focus. Most of the evidence supporting symptomatic FIT pathways came from cohorts dominated by older adults, in whom colorectal cancer is far more common. In younger adults, cancer is much rarer even among those with symptoms, which tends to lower the positive predictive value of any test, while a negative result can be more reassuring but not absolute. Readers should consult the full paper for the pooled sensitivity, specificity and thresholds reported.

Several factors can limit accuracy in this group. Some cancers do not bleed consistently, so a single sample can be falsely negative. Early-onset tumours may differ in location and biology from those in older adults. Benign causes of bleeding, such as haemorrhoids, anal fissures and inflammatory bowel disease, can produce positive results, and these conditions are common in younger people. For these reasons, experts generally stress that FIT should support clinical decision-making rather than replace it, and that patients with persistent or worsening symptoms, or with red-flag features, warrant further assessment even after a negative test.

Why Does Early-Onset Colorectal Cancer Make This Question Urgent?

Quick answer: Colorectal cancer incidence has been rising among adults under 50 in many high-income countries, and younger patients are often diagnosed later because symptoms are attributed to benign causes.

Cancer registries and surveillance reports, including those from the American Cancer Society, have documented increases in colorectal cancer among adults under 50 over recent decades, even as rates have fallen in older adults who benefit from screening. The reasons are not fully understood. Proposed contributors include diet, obesity, physical inactivity, antibiotic exposure, changes in the gut microbiome, and other lifestyle and environmental factors, but no single cause has been established. In response, the US Preventive Services Task Force lowered the recommended starting age for average-risk screening to 45 in 2021.

Younger adults with symptoms are often below the age threshold for screening programmes and may be reassured that bowel changes are probably benign. Studies of early-onset disease have repeatedly noted longer intervals between first symptoms and diagnosis, and more advanced stage at presentation. Better evidence on how FIT performs in symptomatic under-50s could help primary care clinicians decide when a stool test is enough to guide next steps and when direct referral or colonoscopy is more appropriate. Patients should not wait for a test to act on warning signs: persistent rectal bleeding, a lasting change in bowel habit, unexplained weight loss, iron-deficiency anaemia, or a family history of bowel cancer all merit discussion with a doctor.

Frequently Asked Questions

Not completely. FIT can miss some cancers because tumours do not always bleed, and a single sample may not capture intermittent bleeding. If symptoms persist, worsen, or include red-flag features such as anaemia or unexplained weight loss, further evaluation is still advised.

Persistent rectal bleeding, a lasting change in bowel habits, ongoing abdominal pain, unexplained weight loss, and iron-deficiency anaemia should be assessed by a doctor, regardless of age. A family history of colorectal cancer or related conditions raises the importance of prompt evaluation.

No. Screening FIT is offered to people without symptoms at set ages, while symptomatic FIT is used by clinicians to triage people who already have bowel symptoms. The thresholds, expected results, and follow-up pathways can differ.

References

  1. Gut. Diagnostic performance of faecal immunochemical testing (FIT) for colorectal cancer in symptomatic patients under 50 years tested in primary care: a systematic review. (as reported by BMJ News)
  2. National Institute for Health and Care Excellence (NICE). Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care (Diagnostics guidance DG30).
  3. US Preventive Services Task Force. Screening for Colorectal Cancer: Recommendation Statement. JAMA. 2021.
  4. American Cancer Society. Colorectal Cancer Statistics.